Join Inspira Technologies' Live Investor Webinar and Q&A Session on November 11
Join Inspira Technologies' Live Investor Webinar and Q&A Session on November 11
RA'ANANA, Israel, Nov. 8, 2024 /PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN), ("Inspira Technologies" or the "Company"), an innovative medical technology company in the life support and respiratory treatment arena, is pleased to invite investors to a webinar on November 11, 2024, at 4:15 p.m. EST.
以色列拉亞南那,2024年11月8日 / PRNewswire/ - Inspira Technologies Oxy b.H.N. Ltd.(NASDAQ:IINN)(「Inspira Technologies」或「公司」),一家創新的醫療技術公司,專注於生命支持和呼吸治療領域,在2024年11月11日下午4:15邀請投資者參加網絡研討會。
The exclusive event, hosted by RedChip Companies, will feature Joe Hayon, President of Inspira Technologies, who will highlight the Company's developments, including its development of innovative life support technology, designed to monitor and elevate declining blood oxygen saturation levels in minutes without mechanical ventilation, that could disrupt the $19 billion mechanical ventilation market. A live Q&A session will follow the presentation.
這一獨家活動由RedChip Companies主辦,將邀請Inspira Technologies總裁Joe Hayon,他將重點介紹公司的發展,包括其創新的生命支持技術開發,旨在在幾分鐘內監測和提高血氧飽和度下降水平,無需機械通風,可能顛覆190億美元的機械通風市場。演示後將進行現場問答環節。
To register for the free webinar, please visit:
要註冊免費的網絡研討會,請訪問:
Questions can be pre-submitted to [email protected] or online during the live event.
問題可預先發送至[email protected]或在直播期間在線提交。
About Inspira Technologies OXY B.H.N. Ltd.
關於 Inspira Technologies OXY B.H.N. Ltd.
Inspira Technologies is an innovative medical technology company in the life support and respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART), a groundbreaking device poised to revolutionize the $19 billion mechanical ventilation market. With 20 million intensive care unit patients with acute respiratory failure each year, many of whom rely on mechanical ventilators, the INSPIRA ART offers a potential alternative by elevating and stabilizing decreasing oxygen saturation levels in minutes without a ventilator, with patient being awake during treatment. The INSPIRA ART is being equipped with clip-on HYLA blood sensor, a real-time continuous blood monitoring technology, aiming to alert physicians of changes in a patient's condition without the need for intermittent actual blood samples, and potentially supporting physicians in making informed decisions. For more information, visit . Any information displayed on, or that can be accessed through, our website or any other website or any social media is not a part of this press release.
Inspira Technologies是一家創新的醫療技術公司,專注於生命支持和呼吸治療領域。該公司開發了一項突破性的增強呼吸技術(INSPIRA ART),這是一項開創性的設備,有望顛覆190億美元的機械通風市場。每年有2000萬名重症監護病房病人出現急性呼吸衰竭,其中許多人依賴於呼吸機,INSPIRA ART提供了一種潛在的替代方案,可以在幾分鐘內提高和穩定氧飽和度下降水平,無需呼吸機,且患者在治療過程中保持清醒。INSPIRA ART配備了夾式HYLA血液傳感器,一種實時連續血液監測技術,旨在在不需要間斷實際血液採樣的情況下向醫生提供患者情況的變化提示,並潛在支持醫生做出明智決策。欲了解更多信息,請訪問該網站。任何在我們的網站上顯示的信息,或可以通過我們的網站或任何其他網站或社交媒體訪問的信息,均不屬於本新聞稿的一部分。
Forward-Looking Statements
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential size of its target market and that its development of innovative life support technology could disrupt the $19 billion mechanical ventilation market. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website, www.sec.gov.
前瞻性聲明
本新聞稿包含根據美國聯邦證券法規的明示或暗示的前瞻性聲明。這些前瞻性聲明及其影響僅基於公司管理層目前的預期,並受到一系列可能導致實際結果與前瞻性聲明描述不符的因素和不確定性的影響。例如,當公司討論目標市場潛在規模以及其開發的創新生命支持技術可能擾亂價值190億美元的機械通風市場時,公司正在使用前瞻性聲明。這些前瞻性聲明及其影響僅基於公司管理層目前的預期,並受到一系列可能導致實際結果與前瞻性聲明描述不符的因素和不確定性的影響。除非法律另有要求,公司不承諾公開發布對這些前瞻性聲明的修訂,以反映此後事件或情況,或反映未預料到的事件的發生。有關影響公司的風險和不確定性的更詳細信息,請參閱公司於2023年12月31日結束的財政年度提交給美國證券交易委員會(SEC)的20-F表格上的「風險因素」標題下內容,該報告可在SEC網站www.sec.gov上獲得。
Logo:
徽標:
MRK-ARS-121
Copyright 2018-2024 Inspira Technologies OXY B.H.N. LTD. All rights reserved.
MRk-ARS-121
版權 2018-2024 Inspira Technologies OXY b.H.N. LTD. 保留所有權利。
Contact:
For more information, contact:
Inspira Technologies – Media Relations
Email: [email protected]
Phone: +972-9-9664485
聯繫方式:
如需更多信息,請聯繫:
Inspira Technologies – 媒體關係
郵箱:[email protected]
電話:+972-9-9664485
SOURCE Inspira Technologies
來源:Inspira Technologies